Cite
HARVARD Citation
Wu, Y. et al. (2018). Comparison between PD‐1/PD‐L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model. International journal of cancer. 143 (11), pp. 3038-3040. [Online].